Author:
Esmagambetov Ilias B.,Ryabova Ekaterina I.,Derkaev Artem A.,Shcheblyakov Dmitry V.,Dolzhikova Inna V.,Favorskaya Irina A.,Grousova Daria M.,Dovgiy Mikhail A.,Prokofiev Vladimir V.,Gosudarev Andrey I.,Byrikhina Daria V.,Zorkov Ilia D.,Iliukhina Anna A.,Kovyrshina Anna V.,Shelkov Artem Y.,Naroditsky Boris S.,Logunov Denis Y.,Gintsburg Alexander L.
Abstract
IntroductionNumerous agents for prophylaxis of SARS-CoV-2-induced diseases are currently registered for the clinical use. Formation of the immunity happens within several weeks following vaccine administration which is their key disadvantage. In contrast, drugs based on monoclonal antibodies, enable rapid passive immunization and therefore can be used for emergency pre- and post-exposure prophylaxis of COVID-19. However rapid elimination of antibody-based drugs from the circulation limits their usage for prolonged pre-exposure prophylaxis.MethodsIn current work we developed a recombinant adeno-associated viral vector (rAAV), expressing a SARS-CoV-2 spike receptor-binding domain (RBD)-specific antibody P2C5 fused with a human IgG1 Fc fragment (P2C5-Fc) using methods of molecular biotechnology and bioprocessing.Results and discussionsA P2C5-Fc antibody expressed by a proposed rAAV (rAAV-P2C5-Fc) was shown to circulate within more than 300 days in blood of transduced mice and protect animals from lethal SARS-CoV-2 virus (B.1.1.1 and Omicron BA.5 variants) lethal dose of 105 TCID50. In addition, rAAV-P2C5-Fc demonstrated 100% protective activity as emergency prevention and long-term prophylaxis, respectively. It was also demonstrated that high titers of neutralizing antibodies to the SARS-CoV-2 virus were detected in the blood serum of animals that received rAAV-P2C5-Fc for more than 10 months from the moment of administration.Our data therefore indicate applicability of an rAAV for passive immunization and induction of a rapid long-term protection against various SARS-CoV-2 variants.
Subject
Immunology,Immunology and Allergy
Reference30 articles.
1. Coronavirus disease (COVID-19) pandemic
2. WHO director-general's opening remarks at the media briefing on COVID-19
3. Coronavirus (COVID-19) dashboard
4. COVID-19 vaccine tracker and landscape
5. An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine "Sputnik light" for prevention of coronavirus infection in healthy adults;Tukhvatulin;Lancet Reg Health Eur,2021
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献